IMPLICATIONS OF FLEROXACINS PHARMACOKINETIC PROFILE

被引:1
|
作者
NIGHTINGALE, CH
机构
[1] Hartford Hospital, Hartford, CT 06115
关键词
FLEROXACIN; PHARMACODYNAMICS; ELIMINATION; ABSORPTION; BODY DISTRIBUTION; DRUG INTERACTIONS;
D O I
10.1016/0924-8579(94)90016-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Fleroxacin, like all quinolones, is well absorbed, reaching peak concentrations within 2 h. Interactions with Ca2+ and Al3+ are minimal compared with other quinolones and possibly of little clinical importance. The drug is eliminated via filtration in the kidney. It is therefore sensitive to changes in renal function. Accumulation of drug in the body is minimal, and change from intravenous to oral dosing results in nearly identical serum concentrations. Aside from the modest effect of metals on its absorption, fleroxacin does not interact/compete with substances oxidized in the liver, such as theophylline, and drug interactions are minimal. Its long serum half-life (8-12 h) allows once-a-day dosing. This may be of particular pharmacodynamic advantage when treating infections caused by organisms with relatively high MIC's. This feature, along with its modest drug interactions, indicates that fleroxacin will probably be an important quinolone useful in a variety of clinical settings.
引用
收藏
页码:S7 / S13
页数:7
相关论文
共 50 条
  • [1] Pharmacokinetic Profile of Oral Magnesium Hydroxide
    Dolberg, Mette Konow Bogebjerg
    Nielsen, Lars Peter
    Dahl, Ronald
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 120 (03) : 264 - 269
  • [2] Effect of multidose cilostazol on pharmacokinetic and lipid profile of atorvastatin in male Wistar rats
    Vats, Rahul
    Varanasi, Kanthikiran V. S.
    Arla, Rambabu
    Veeraraghavan, Sridhar
    Rajak, Shraddha
    Murthy, Aditya Narasimha
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2012, 64 (11) : 1638 - 1645
  • [3] Pharmacokinetic profile of levetiracetam: toward ideal characteristics
    Patsalos, PN
    PHARMACOLOGY & THERAPEUTICS, 2000, 85 (02) : 77 - 85
  • [4] The pharmacokinetic profile of fesoterodine: Similarities and differences to tolterodine
    Simon, Hans-Uwe
    Malhotra, Bimal
    SWISS MEDICAL WEEKLY, 2009, 139 (9-10) : 146 - 151
  • [5] Pharmacokinetic profile and behavioral effects of gabapentin in the horse
    Terry, R. L.
    McDonnell, S. M.
    van Eps, A. W.
    Soma, L. R.
    Liu, Y.
    Uboh, C. E.
    Moate, P. J.
    Driessen, B.
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2010, 33 (05) : 485 - 494
  • [6] Pharmacokinetic profile of defibrotide in patients with renal impairment
    Tocchetti, Paola
    Tudone, Elena
    Marier, Jean-Francois
    Marbury, Thomas C.
    Zomorodi, Katie
    Eller, Mark
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 2631 - 2641
  • [7] Single Dose Oral Pharmacokinetic Profile of α-Mangostin in Mice
    Ramaiya, Atulkumar
    Li, Gongbo
    Petiwala, Sakina M.
    Johnson, Jeremy J.
    CURRENT DRUG TARGETS, 2012, 13 (14) : 1698 - 1704
  • [8] Pharmacokinetic and pharmacodynamic implications in inhalable antimicrobial therapy
    Mukker, Jatinder Kaur
    Singh, Ravi Shankar Prasad
    Derendorf, Hartmut
    ADVANCED DRUG DELIVERY REVIEWS, 2015, 85 : 57 - 64
  • [9] Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation
    Angiolillo, Dominick J.
    Prats, Jayne
    Deliargyris, Efthymios N.
    Schneider, David J.
    Scheiman, James
    Kimmelstiel, Carey
    Steg, Ph Gabriel
    Alberts, Mark
    Rosengart, Todd
    Mehran, Roxana
    Bhatt, Deepak L.
    CLINICAL PHARMACOKINETICS, 2022, 61 (04) : 465 - 479
  • [10] Pharmacokinetic variability of anthelmintics: implications for the treatment of neurocysticercosis
    Jung-Cook, Helgi
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2012, 5 (01) : 21 - 30